BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice

The treatment of multiple myeloma (MM) is evolving rapidly. In the past few years, chimeric antigen receptor modified T cells and bispecific antibodies are bringing new treatment options to patients with relapsed/refractory MM. Currently, B-cell maturation antigen (BCMA) has emerged as the most comm...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiang, Rasche, Leo, Kortüm, K. Martin, Mersi, Julia, Einsele, Hermann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071122/
https://www.ncbi.nlm.nih.gov/pubmed/36263838
http://dx.doi.org/10.3324/haematol.2020.266841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071122/
https://www.ncbi.nlm.nih.gov/pubmed/36263838
http://dx.doi.org/10.3324/haematol.2020.266841

Ejemplares similares